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logical cancer, the meeting of which this
book is the proceedings acted as an important
focal point for the appraisal of current treat-
ment and research, and provided a forum to
discuss new directions for the future. Because
of the large number of papers on various
bladder-cancer topics (28 chapters on aspects
of staging and experimental pathology, 17
on surgical treatment, 9 on radiotherapy, 23
on chemotherapy) most of the chapters are
short data presentations, mostly new or an
update ofpreviously published work. Bladder
cancer is a disease which is predominantly
managed by surgeons. The chapters on the
variety of surgical approaches possible are
well presented, but the format ofthe chapters
gives little chance for an overall appraisal
of the relative merits of different approaches.
Perhaps the most fundamental question
raised was the relevance oflymph-node clear-
ance at cystectomy. Although manyEuropean
and American surgeons prefer the radical
technique because it simplifies the access to
remove the bladder, there is no data to
demonstrate its superiority over simple
cystectomy. The data reported from two
Dutch groups in fact demonstrates that, as in
carcinoma of the breast, the results from the
simple operation are as good and suggest that
there are less post-operative complications.
The papers on radiotherapy were not as
extensive as on surgical aspects, but there are
good contributions on the relative merits
and pelvic complications from use of 6 MeV
linear accelerator and Cobalt-60 therapy,
demonstrating the normal-tissue-sparing
effect from the former.
Chemotherapy for treatment of advanced
bladder cancer is not new, but only recently
has it become clear that this disease is as
chemoresponsive to single-agent therapy as
breast and head and neck tumours, justifying
trials of adjuvant therapy. Two pilot studies
with encouraging results are reported, but it
will be several years before data is available
from controlled trials.
Intravesical topical chemotherapy ofsuper-
ficial tumours has a long history, and although
new information demonstrating activity of
adriamycin and cis-platinum is presented, all
agents tested to date have about the same
level of activity. The lack of advantage of
these new drugs over the cheaper, long-
e3tablished agents Thiotepa and Epodyl,
makes it unlikely that they will be first-line
treatment.
Compared to the extensive data on bladder
cancer in this book, there were only a few
papers on cancer of the prostate (10, 4 of
which dealt with aspects of hormone recep-
tors) and 2 papers on testicular tumours. The
most important of these papers is an update
ofinformation from the Veterans Administra-
tive Prostatic Cancer trials, which have
caused considerable controversy in the U.S.A.
by suggesting that there is no place for radical
surgeryorearlyadjuvantendocrine manipula-
tion in this disease.
Although this book will probably be of
greatest value to surgeons in training or
involved in clinical research in urological
tumours, the fund of information and refer-
ences will be of considerable interest to
radiotherapists and oncologists needing an
introduction to the treatment of urological
cancer.
R. J. D. OLIVER
Fast Neutrons in the Treatment of
Cancer. M. CATTERALL & D. K. BEWLEY
(1979) London: Academic Press. 394 pp.
£22.40.
The cyclotron at the MRC Cyclotron Unit
at Hammersmith Hospital in London has
now been in use for 25 years, as a source of
radioisotopes for research and clinical use,
as a research tool for radiobiologists and as a
neutron source for radiotherapy. This book
gives an account ofthe pioneering work ofthe
Hammersmith team indevelopingthephysical
and biological background for neutron ther-
apy, and the subsequent 10 years of clinical
experience and clinical trials.
The first 3 chapters, on the discovery of
the neutron and the development of the
medical cyclotron, the production of neutron
beams, and the interaction of neutrons with
matter; dosimetry; depth-dose, give a wide-
ranging review of these basic topics with
adequate references to the now extensive
literature. Chapter 4, on radiobiological
aspects of neutron therapy, gives an account
of the basic radiobiology of fast neutrons,
and develops the biological arguments which
justify clinical experiments on the use of
fast neutrons for the treatment of cancer.
Quite properly, the emphasis in these chapters
is ontheworkdoneatHammersmithHospital,
as this has provided the basic data on whichBOOK REVIEWS
the clinical work described in subsequent
chapters is based.
Chapter 5, on techniques of treatment, dis-
cusses the uses ofthe fixed horizontal beam of
neutrons, with "poor penetration, rounded
isodose curves, rather wide penumbra, high
skin dose" and the ingenious methods that
have been developed to overcome these
limitations. The chapter discusses the use of
bolus, wedge filters and field shaping devices,
patient immobilizing systems and verification
films (neutrograms) for the careful design of
individual treatments with the 7MeV (mean
energy) neutron beam available from the
cyclotron. As neutron beams are always
accompanied by y-rays, there has been much
discussion of methods of specifying the dose
delivered in a neutron-beam treatment,
and this chapter describes and justifies the
Hammersmith system of quoting the neutron
dose only. In these terms, most of the treat-
ments described in the clinical chapters have
received a standard regime of 15-6 Gy of
neutrons to the tumour, given in 12 fractions
over 26 days at 3 fractions per week. The
accompanying small dose ofy-rays is regarded
as negligible, because of their low RBE in
comparison with the neutron component.
The 3 fractions per week regime was dictated
by the availability of the cyclotron.
The chapter on design of clinical investiga-
tions describes observations on skin reactions,
and malignant skin nodules when given frac-
tionated irradiation neutron beam. Estimates
of the clinical RBE, and the subsequent
standard dose regime were based on these
observations. This chapter lays emphasis on
the need for detailed accurate and frequent
recording of patient reactions and responses.
The 6 clinical chapters give very detailed
accounts of the techniques and results of
treatments, for head and neck, the brain, the
thorax, the abdomen and pelvis as well as a
chapter on very large tumours, sarcoma,
chordoma, breast, melanoma, and recurrent
tumours. These chapters are well illustrated
with treatment plans, tabular material about
reactions, complications andresults,andmany
before and after pictures. The results of two
prospective clinical trials comparing neutron
and photon treatments for brain and for head
and neck tumours are given. For the brain
trial there was no significant difference
between neutrons and photon treatments, in
terms oftumourregression orpatient survival.
In the head and neck trial, there were about
80 patients on each ofthe neutron and photon
arms, and complete tumour regression at
about 60o% and 250% in the neutron and
photon arms washighlysignificantly different.
It should be emphasized that these results
were obtained with patients with relatively
advanced disease. Very little information is
given about the patients, the techniques of
treatment, or doses in the photon arms of
these clinical trials, and this makes it difficult
for the reader to arrive at a critical judgement
of the results. It might also be considered
that the use of a standard dose for all the
neutron treatments limits the usefulness of
the clinical observations. This point is to
some extent taken up in Chapter 14, which
considers the reactions oftumours and normal
tissue to this standard dose of neutrons. It is
considered that, at a non-statistical level,
many types of tumour show a marked
improvement in local control when irradiated
by neutrons rather than photons. The
complications observed in normal-tissue reac-
tions are discussed, and are considered to be
in part because the available neutron beam
is comparable to a 250 kV X-ray beam in
penetration and beam definition, and in these
respects, as well as in terms ofbeam mobility,
is very inferior to what is currently available
for megavoltage X-ray theiapy. The reduced
absorption of neutrons in bone is, however,
an advantage and may reduce the incidence
of bone necrosis, while increased absorption
in fat may lead to increased problems with
fibrosis. This chapter also includes a brief
review ofother recent clinical trials in neutron
therapy, all of which are at an earlier stage
than the Hammersmith work. Although most
of these trials are far from completed, the
results at other centres show a greater pro-
portion of residual and recurrent tumours
and that observed at Hammersmith. How-
ever, the authors are of the opinion that the
omens are stillfavourable for neutrontherapy.
The final chapter, "Lessons learned and
the way ahead", emphasizes that good local
control ofadvanced tumours requires extreme
care and attention to details, and pursues this
idea at some length. The authors are of the
opinion that neutron therapy can only be
adequately tested by using a high-energy
cyclotron which will give neutron beams of
comparable penetrating power and steer-
ability to those available for photon therapy.
This book is well produced, and well
illustrated by photographs, graphs and tables.
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The authors' enthusiasm for their subject
comes through in the quality of the writing,
and their book will become part of the re-
quired reading for anyone who wishes to take
a serious interest in neutron therapy.
D. GREENE
R. S. POINTON
Cancer Treatment. Ed. C. M. HASKELL
(1980) London: W. B. Saunders & Co.
1133 pp. £27.75.
Cancer Treatment was written as a succinct
"state of the art" book for physicians who
are responsible for the overall care ofpatients
with cancer. The multidisciplinary nature of
modern therapy is emphasised by Charles
Haskell and his colleagues from Los Angeles.
Part 1 of the book deals with the disciplines
relevant to cancer therapy, including surgery,
radiation therapy, chemotherapy, and im-
munotherapy. The disease-orientated chap-
ters which follow in Part II discuss the
contemporary role of each of the oncologic
specialities in cancer treatment. Part III deals
with selective complications of cancer and
its treatment. The contributors are to be
congratulated on producing reviews which are
clear, easily read, comprehensive and un-
biased. The limitations ofcertainexperimental
therapies are clearly stated. It was dis-
appointing, however, that less than 1 page
was devoted to discussion of the role of adju-
vant chemotherapy in breast cancer. There is
good practical advice on the management of
bone marrow failure, malignant pleural
effusions, superior vena caval obstruction,
para-neoplastic syndromes, pain, rehabilita-
tion, and last but not least psychosocial
problems.
This book succeeds in its aim and is the
best of the recent publications on clinical
oncology. It can be strongly recommended to
all interested in the management of patients
with cancer.
J. H. SCARFFE
Preleukemic Disorders. L. KASS (1980)
Springfield: Charles C. Thomas. 189 pp.
Price $21.75.
The purist will define the term 'preleukae-
mia" as the haematological syndrome which
precedes overt leukaemia, but which is not,
at the time, diagnostic of it. For many years,
haematologists have been aware that abnor-
malities such as unexplained red-cell macro-
cytosis, cytopenias, monocytosis, morpho-
logical abnormalities ofmonocytes and granu-
locytes, often accompanied by evidence of
disordered maturation of one or all cell lines
in the marrow, may be prodromas of myelo-
blastic leukaemia or its morphological vari-
ants. Some, though by no means all patients
with these abnormalities will eventually
develop leukaemia, and some authorities have
criticised the term as being valid only as a
retrospective diagnosis. The label has now,
however, been used to cover a wider spectrum
ofblood and marrow pictures which, together,
are frequently referred to as oligoblastic or
'.smouldering" leukaemia. This is logical
because they merge imperceptibly into the
less specific features of the original pre-
leukaemic syndrome, the main difference
being that they show a definite increase in
marrow blasts. In a sense, they might be
regarded as differing from acute leukaemia
quantitatively rather than qualitatively. After
enumerating the blood and marrow findings
of the non-specific pre-leukaemia syndrome,
the present volume reviews in detail the 3
major morphological variants of oligoblastic
leukaemia: "primary acquired panmyelo-
pathy with myeloblastosis" (also known in
the European literature as "refractory
anaemia with excess of blasts") erythro-
leukaemia, and subacute myelomonocytic
leukaemia. As well as a description of the
distinctive morphological features, as seen
by electron and light microscopy, Dr Kass
discusses the cytochemical, metabolic, cyto-
genetic and possible pathophysiological abnor-
malities which characterise each type. Al-
though some of the material has appeared
in the author's earlier book on refractory
anaemias, the chapter on erythroleukaemia
is excellent, and includes a topical discussion
ofthe virus-induced disease seen in mice.
The difficulty is in knowing whether these
morphological entities are also clinical entities
or part of a continuous spectrum of myelo-
dysplasia which results from leukaemic
transformation ofthe haemopoietic stem cell;
the precise picture which results may depend
as much on micro-environmental influences
as on the intrinsic behaviour ofthe leukaemic
cell line; in this context, a parallel might be
drawn with the chronic myeloproliferative
disorders.